Abstract
Most of the published works so far have aimed at finding genes associated with multiple sclerosis (MS) susceptibility. Very few studies have attempted to correlate disease features with DNA variants. In a well-characterized sample (651 patients) representative of multiple sclerosis natural history, we engaged a comprehensive study of the role of human leukocyte antigen (HLA) in the course of the disease. We investigated the role of HLA-DRB1*15 allele in samples stratified according to severity evaluated by the Multiple Sclerosis Severity Score (MSSS), time to reach EDSS 6.0 and disease type. We found that HLA-DRB1*15 genotype does not influence MS severity even among patients presenting with a given type of the disease. However, we show for the first time that HLA-DRB1*15 allele modulates the course of MS for relapsing–remitting (RR) onset patients likely by precipitating the secondary progressive (SP) phase.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 digital issues and online access to articles
$119.00 per year
only $19.83 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hauser SL, Oksenberg JR . The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006; 52: 61–76.
Compston DA, Kellar Wood H, Robertson N, Sawcer S, Wood NW . Genes and susceptibility to multiple sclerosis. Acta Neurol Scand Suppl 1995; 161: 43–51.
Ebers GC, Dyment DA . Genetics of multiple sclerosis. Semin Neurol. 1998; 18: 295–299.
Jersild C, Fog T . Histocompatibility (HL-A) antigens associated with multiple sclerosis. Acta Neurol Scand Suppl 1972; 51: 377.
Gregory SG, Schmidt S, Seth P, Oksenberg JR, Hart J, Prokop A et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007; 39: 1083–1091.
Lundmark F, Duvefelt K, Iacobaeus E, Kockum I, Wallstrom E, Khademi M et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet 2007; 39: 1108–1113.
Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357: 851–862.
Ramagopalan SV, Anderson C, Sadovnick AD, Ebers GC . Genomewide study of multiple sclerosis. N Engl J Med 2007; 357: 2199–2200; author reply 2200–2201.
Weber F, Fontaine B, Cournu-Rebeix I, Kroner A, Knop M, Lutz S et al. IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Genes Immun 2008; 9: 259–263.
Olsson T, Jagodic M, Piehl F, Wallstrom E . Genetics of autoimmune neuroinflammation. Curr Opin Immunol 2006; 18: 643–649.
Lublin FD, Reingold SC, National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 907–911.
Weinshenker BG . The natural history of multiple sclerosis: update 1998. Semin Neurol 1998; 18: 301–307.
Stankoff B, Mrejen S, Tourbah A, Fontaine B, Lyon-Caen O, Lubetzki C et al. Age at onset determines the occurrence of the progressive phase of multiple sclerosis. Neurology 2007; 68: 779–781.
Confavreux C, Vukusic S . Natural history of multiple sclerosis: a unifying concept. Brain 2006; 129 (Part 3): 606–616.
Kantarci O, Wingerchuk D . Epidemiology and natural history of multiple sclerosis: new insights. Curr Opin Neurol 2006; 19: 248–254.
Hensiek AE, Seaman SR, Barcellos LF, Oturai A, Eraksoi M, Cocco E et al. Familial effects on the clinical course of multiple sclerosis. Neurology 2007; 68: 376–383.
DeLuca GC, Ramagopalan SV, Herrera BM, Dyment DA, Lincoln MR, Montpetit A et al. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Natl Acad Sci USA 2007; 104: 20896–20901.
Brassat D, Azais-Vuillemin C, Yaouanq J, Semana G, Reboul J, Cournu I, et al., French Multiple Sclerosis Genetics Group. Familial factors influence disability in MS multiplex families. Neurology 1999; 52: 1632–1636.
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121–127.
Kurtzke JF . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1452.
Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S et al. Multiple sclerosis severity score: using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144–1151.
Barcellos LF, Oksenberg JR, Begovich AB, Martin ER, Schmidt S, Vittinghoff E et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 2003; 72: 710–716.
Barcellos LF, Sawcer S, Ramsay PP, Baranzini SE, Thomson G, Briggs F et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 200615; 15: 2813–2824.
Umbach DM, Weinberg CR . The use of case-parent triads to study joint effects of genotype and exposure. Am J Hum Genet 2000; 66: 251–261.
Venken K, Hellings N, Hensen K, Rummens JL, Medaer R, D'Hooghe MB et al. Secondary progressive in contrast to relapsing–remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression. J Neurosci Res 2006; 83: 1432–1446.
Acknowledgements
This study was supported by grants from INSERM (Réseau de Recherche Clinique), the Association pour la Recherche sur la SEP (ARSEP), groupe Malakoff, Biogen Idec, the Association Française contre les Myopathies (AFM) and AP-HP (contrat interface ICR). We acknowledge the active collaboration of members of the REFGENSEP (Réseau Français d'Etude Génétique de la SEP), Généthon and Centre d'Investigation Clinique Pitié-Salpêtrière.
Author information
Authors and Affiliations
Corresponding author
Additional information
Disclosure
The authors state no conflict of interest.
Supplementary Information accompanies the paper on Genes and Immunity website (http://www.nature.com/gene)
Supplementary information
Rights and permissions
About this article
Cite this article
Cournu-Rebeix, I., Génin, E., Leray, E. et al. HLA-DRB1*15 allele influences the later course of relapsing remitting multiple sclerosis. Genes Immun 9, 570–574 (2008). https://doi.org/10.1038/gene.2008.52
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gene.2008.52